Eli Lilly & Co. vs Novavax Inc
LLY vs NVAX — side-by-side comparison from reported financials. LLY leads 7, NVAX leads 3 of 10 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Novavax Inc
NVAX · Healthcare
$12.73+15.62%Strong
| Metric | LLY | NVAX |
|---|---|---|
| Price | $1 177.20 | $12.73 |
| Market cap | $1.05T | $2.10B |
| Revenue (TTM) | $79.7B | $414M |
| Revenue growth | +31.7% | -17.2% |
| Net margin | 33.5% | -59.9% |
| Free cash flow | $18.2B | -$42.8M |
| Net cash (debt) | ($35.2B) | — |
| 1-year price return | +37.6% | +48.2% |
| P/E | 41.6 | 4.8 |
| P/E vs own history (cheap-side %) | 88% | 29% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | 283% |
| Altman Z-score | 7.10 | -5.14 |
| CV checks passed | 11 of 11 | 4 of 11 |
| Employees | 50,000 | 749 |
Full résumé-style profiles: LLY CV · NVAX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.